Hainan General Hospital
Hainan General Hospital
Haikou, Hainan, China21 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE) | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Enrolling by invitation | Phase 3 | 2026-10-05 | NCT05352919 | |
| A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-09-10 | NCT06561607 | |
| A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma | Disease Attributes, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Recurrence, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Active, not recruiting | Phase 2 | 2026-08-31 | NCT05126719 | |
| A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-08-14 | NCT05869903 | |
| DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction | Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not stated | 2026-08-12 | NCT07761390 | |
| A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 3 | 2026-07-08 | NCT05070858 | |
| Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 3 | 2026-06-25 | NCT07385703 | |
| TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer | HER2-positive Advanced Breast Cancer | Recruiting | Phase 3 | 2026-06-03 | NCT07047365 | |
| Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) | Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | Phase 3 | 2026-05-29 | NCT07165951 | |
| A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 2 | 2026-05-27 | NCT06991257 | |
| China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Not stated | 2026-04-28 | NCT05498974 | |
| Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-03-27 | NCT05147467 | |
| A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 3 | 2026-01-29 | NCT04961567 | |
| A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 3 | 2025-10-15 | NCT06280716 | |
| Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 3 | 2025-09-23 | NCT07187960 | |
| Clinical Trial of BAO-G Technique in Complex Aortic Aneurysm Endovascular Repair (BAO-G-02) | Aneurysm, Aortic Aneurysm, Thoracoabdominal, abdominal aortic aneurysm, aortic aneurysm, aortic disorder, cardiovascular disorder, vascular disorder | Recruiting | Phase 1 | 2025-09-05 | NCT07141251 | |
| Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2025-08-14 | NCT07008976 | |
| Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC | Disease Attributes, Disease Progression, Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Stomatognathic Diseases, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 2 | 2025-07-01 | NCT06811844 | |
| A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Active, not recruiting | Phase 3 | 2025-04-13 | NCT04974398 | |
| A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) | Advanced Hepatocellular Carcinoma (HCC) | Active, not recruiting | Phase 3 | 2025-02-20 | NCT04344158 | |
| A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, thalassemia | Recruiting | Phase 1 | 2025-01-14 | NCT06772766 |